|
|
新型冠状病毒肺炎疫情期回望氯喹发展史 |
赵绵松 |
100038,首都医科大学附属北京世纪坛医院风湿免疫科 |
|
[1] |
Salata C, Calistri A, Parolin C, et al. Coronaviruses: a paradigm of new emerging zoonotic diseases[J]. Pathog Dis. 2020 Feb 17. pii: ftaa006. doi: 10.1093/femspd/ftaa006.[Epub ahead of print].
|
[2] |
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, doi: 10.1056/ NEJMoa2001017.[Epub ahead of print].
|
[3] |
国家卫生健康委办公厅.关于印发新型冠状病毒肺炎防控方案 (第五版)的通知疾病预防控制局国卫办疾控 函〔2020〕103号[EB/OL]. (2020-02-06)[2020-02-14]. http://www.nhc.gov.cn/jkj.
|
[4] |
Klein W, Pieter T. The hidden history of a famous drug: tracing the medical and public acculturation of peruvian bark in early modern Western Europe (c. 1650-1720)[J]. J Hist Med Allied Sci, 2016, 71: 400-421.
|
[5] |
Earle D. Presidential address: a history of malaria and its ironies [J]. Trans Am Clin Climatol Assoc, 1979, 90: 1-26.
|
[6] |
Harrison N. In celebration of the Jesuit’s powder: a history of malaria treatment [J]. Lancet, 2015, 15: 1143.
|
[7] |
Gachelin G, Garner P, Ferroni E, et al. Evaluating Cinchona bark and quinine for treating and prventing malaria [J]. J R Soc Med, 2017, 110(1) 31-40.
|
[8] |
Brabin B. Malaria’s contribution to World War One-the unexpected adversary [J]. Malar J, 2014, 13, 497.
|
[9] |
Slater A, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites[J]. Nature,1992, 355: 167-169.
|
[10] |
Olafsona K N, Nguyena T Q , Jeffrey D, et al. Antimalarials inhibit hematin crystallization by unique drug-surface site interactions[J]. Proc Natl Acad Sci USA, 2017, 114: 7531-7536.
|
[11] |
Ramanna M, Nasarwanji H, Choksy (1861-1939). A pioneer of controlled clinical trials. JLL Bulletin: Commentaries on the history of treatment evaluation, 2014. www.jameslindlibrary.org/articles/nasarwanji-hormusji-choksy-1861-1939-a-pio-neer-of-controlled-clinical-trials/ (last checked 13 November 2016).
|
[12] |
Liles N W, Page E E,. Liles A L, et al . Diversity and severity of adverse reactions to quinine: a systematic review[J]. Am J Hematol, 2016, 91: 461-466.
|
[13] |
Reva C L, David T F, Charles G H,et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I[J]. Arthritis Rheum, 2007, 58:15-25.
|
[14] |
Marks J. S. Motor polyneuroapthy and nystagmus associated with chloroquine phosphate[J]. Postgrad Med J, 1979, 55(646): 569.
|
[15] |
Durcan L, Petri M. Immunomodulators in SLE: clinical evidence and immunologic actions[J]. J Autoimmun, 2016,74: 73-84.
|
[16] |
Julie B, Nathalie C C, Adey B. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus [J]. Ann Rheum Dis, 77(12): 1742-1749.
|
[17] |
Graciela S A, Gerald M, Ana M, et al Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) [J]. Ann Rheum Dis, 2007, 66(9): 1168-1172.
|
[18] |
Kroese S, Hair J. Hydroxychloroquine Use in Lupus patients during pregnancy is associated with longer pregnancy duration in preterm births [J]. J Immunol Res, 2017, 2017: 2810202.
|
[19] |
Jacob H R, Wu Xiao-Xuan. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein-I complexes to phospholipid bilayers [J]. Blood, 2008, 112(5): 1687-1695.
|
[20] |
O’Dell J R, Mikuls T R, Taylor T H, et al. Therapies for active rheumatoid arthritis after methotrexate failure[J]. N Engl J Med, 2013, 369(4): 307-318.
|
[21] |
WANG S Q, ZHANG L W, WEI P. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis [J]. BMC Musculoskelet Disord, 2017, 18: 186.
|
[22] |
Fazlollah K. Fungistatic effect of hydroxychloroquine, lessons from a case [J]. Med Mycol Case Rep, 2016, 13: 17-18.
|
[23] |
Marcos C B,Luiza A, Castro B, et al. Chloroquine use improves dengue-related symptoms[J]. Mem Inst Oswaldo Cruz, 2013, 108(5): 596-599.
|
[24] |
Andrea S, Iart L S. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS [J]. Retrovirology, 2015, 12: 51.
|
[25] |
Helal G K, Gad M A, Abd-Ellah M F, et al. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients[J]. J Med Virol,2016,88:2170-2178.
|
[26] |
Solomon D H, Garg R, LIU B, et al. The effect of hydroxychloroquine on insulin sensitivity and lipid parameters in non-diabetic patients with rheumatoid arthritis: a randomized blinded cross-over trial arthritis [J]. Care Res (Hoboken), 2015, 66(8): 1246-1251.
|
[27] |
Arielle U, Nicholas T, Cristina S, et al. Inflammation beyond the joints:rheumatoid arthritis and cardiovascular disease[J]. J Cardiol,2018,2(3):1000019.
|
[28] |
Jose F R, Inmaculada R, Emily M, et al.Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients[J]. J Clin Rheumatol, 2017, 23(3): 144-148.
|
[29] |
Li X F, Burton E M, Bhaduri-McIntosh S, et al . Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells [J]. PLoS Pathog, 2017, 13(3): e1006249.
|
[30] |
Jia Lihua, Wang Juan, Wu Tong. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma[J]. Mol Med Rep, 2017, 16(5): 5779-5786.
|
[31] |
刘 佳,陈芳源,王海嵘. 磷酸氯喹诱导 U937细胞凋亡机制的研究[J]. 上海交通大学学报 (医学版),2009, 29(7): 813-816
|
[32] |
Chen Degao, Xie Jing, Roland F, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype [J]. Nat Commun, 2018, 9: 873.
|
[33] |
Melisa N, Taylor S B, Paul E, et al. Are long-term chloroquine or hydroxychloroquine users being checked regularly for toxic maculopathy?[J]. JAMA Ophthalmol, 2014,132(10): 1199-1208.
|
[34] |
Martin J V, Bergeron E, Suzanne B, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virol J, 2005, 2: 69.
|
[35] |
Rodrigo D, Luiza M. H, Paula P. et al. Chloroquine, an endocytosis blocking agent, inhibits Zika Virus infection in different cell models[J]. Viruses,2016, 8(12): 322.
|
[36] |
De Wilde A H, Jochmans D, Posthuma C C, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture[J]. Antimicrob Agents Chemother, 2014, 58(8):4875-4884.
|
[37] |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 6736(20): 30183-30185.
|
[38] |
Steinbuch Y. Chinese baby tests positive for Coronavirus 30 hours after birth[N/OL]. (ac-cessed on 9 February 2020),Available online: https://nypost.com/2020/02/05/chinese-baby-tests-positive-for-coronavirus-30-hours-after-birth/.
|
[39] |
Gillespie T. Coronavirus: doctors fear pregnant women can pass on illness after newborn baby is diagnosed[N/OL]. (accessed on 8 February 2020), Available online: https://news.sky.com/story/coronavirus-doctors-fear-pregnant-women-can-pass-on-illness-after-newborn-baby-is-diagnosed-11926968.
|
[1] |
陈孝储, 侯晓杰, 李正超, 付宝成, 何飞, 郭一沙, 韩晨光, 贾志龙, 望叙. 某医学中心应对新型冠状病毒肺炎疫情“四分法”管理模式探索与实践[J]. 武警医学, 2020, 31(4): 340-342. |
[2] |
郭春良, 王风云, 陈旭义, 王仁杰, 陈淑莲, 关树梅, 刘军. 基于新冠肺炎病理解剖及免疫改变的中西医结合治疗探讨[J]. 武警医学, 2020, 31(4): 349-350. |
[3] |
王智达, 熊杰. 新型冠状病毒肺炎中医论治浅析[J]. 武警医学, 2020, 31(4): 361-362. |
[4] |
郭俊玲, 侯亚红, 臧红新. 新型冠状病毒肺炎救治医护人员个人防护装备穿脱流程及关键点初探[J]. 武警医学, 2020, 31(4): 363-365. |
[5] |
段力萨, 郭宇明, 孙江男, 江雨桐, 姜荣环, 苏彬. 新冠肺炎疫情下某部队三甲医院官兵员工心理健康状况调查分析[J]. 武警医学, 2020, 31(3): 191-194. |
[6] |
徐欣, 王斐, 郝雪梅, 刘慧, 许秀萍. 某三甲医院新型冠状病毒肺炎疫情期发热门诊的管理实践[J]. 武警医学, 2020, 31(3): 257-258. |
[7] |
向海兵, 马郡, 徐红岩, 刘积平, 唐子滨, 曹雷. 队属医院应对新型冠状病毒肺炎疫情防控工作策略[J]. 武警医学, 2020, 31(3): 259-260. |
[8] |
赵鹏, 贾志龙, 戴卫民. 应对新型冠状病毒肺炎医疗队的组队管理模式探讨[J]. 武警医学, 2020, 31(3): 261-262. |
[9] |
陈孝储, 何飞, 张海龙, 李正超, 贾志龙, 王振国. 某军队综合医院应对新型冠状病毒肺炎疫情防控策略与实践[J]. 武警医学, 2020, 31(3): 263-264. |
[10] |
卢明明, 袁飞. 2019新型冠状病毒肺炎(COVID-2019)影像学特征的研究进展[J]. 武警医学, 2020, 31(3): 265-268. |
[11] |
陈凯, 苏彬, 杨易, 王振国. 新型冠状病毒肺炎病原学及临床特点研究进展[J]. 武警医学, 2020, 31(3): 269-271. |
[12] |
汤芳, 王晓芹, 栾进, 佟宇浩, 曹德康. 新型冠状病毒肺炎的流行病学研究进展[J]. 武警医学, 2020, 31(3): 272-276. |
[13] |
张梅, 李闯. 新型冠状病毒肺炎与心血管疾病[J]. 武警医学, 2020, 31(2): 93-96. |
[14] |
李大江, 李念, 杜鑫, 刘凯, 曾勇, 宗志勇, 陈敏, 吴晓东. 新型冠状病毒肺炎医疗救治体系化建设的探索与实践[J]. 武警医学, 2020, 31(2): 97-99. |
[15] |
曾国彬;张创成. 磷酸氯喹预防透析痉挛发作20例报告[J]. , 1997, 08(03): 145-145. |
|
|
|
|